MODIFIZIERTE ADENOVIREN
European patent · EP3737403 · In force
Register entry
- Publication number
- EP3737403
- Application number
- EP19711157
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Feb 13, 2019
- Published
- Nov 18, 2020
- Granted
- Jan 3, 2024
- Protection ends at the latest
- Feb 12, 2039
- Next annual fee due
- Feb 28, 2027
- IPC classes
- A61K 38/16 (2006.01)A61K 38/48 (2006.01)C07K 14/005 (2006.01)C12N 7/00 (2006.01)
- Priority
- GB 201802539 16.02.2018
- PCT application
- PCT/GB2019/050380 13.02.2019
- PCT publication
- WO2019/158914 22.08.2019
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Mar 1, 2026
Change
Published in Swissreg on 01.03.2026
- Mar 1, 2025
Change
Published in Swissreg on 01.03.2025
- Nov 13, 2024
Change
Published in Swissreg on 13.11.2024
- Aug 8, 2024
Licensee entered
- License holder
- Trocept Therapeutics Limited, Lashford House Chu rch Lane, Dry Sandford, A bingdon, Oxford OX13 6JP, United Kingdom
Published in Swissreg on 08.08.2024
- Mar 1, 2024
Change
Published in Swissreg on 01.03.2024
- Jan 10, 2024
Agent entered
- Representative
- MICHELI & CIE SA, 122, rue de Genève,, CP 61, 1226 Thônex
Published in Swissreg on 10.01.2024
- Jan 3, 2024
Granted
Published in Swissreg on 03.01.2024
Parties
Inventor
PARKER, Alan
Cowbridge, South Glamorgan CF71 7LJ, GB
UUSI-KERTTULA, Hanni
00100 Helsinki, FI
Licensee
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.